Epidemiological observations and molecular-level experiments have indicated that brain disorders in the realm of psychiatry may be influenced by immune dysregulation. However, the degree of genetic overlap between immune disorders and psychiatric disorders has not been well established. We investigated this issue by integrative analysis of genome-wide association studies (GWAS) of 18 complex human traits/diseases (five psychiatric disorders, seven autoimmune disorders, and others) and multiple genomewide annotation resources (Central nervous system genes, immune-related expressionquantitative trait loci (eQTL) and DNase I hypertensive sites from 98 cell-lines). We detected pleiotropy in 24 of the 35 psychiatric-autoimmune disorder pairs, with statistical significance as strong as p=3.9e-285 (schizophrenia-rheumatoid arthritis). Strong enrichment (>1.4 fold) of immune-related eQTL was observed in four psychiatric disorders. Genomic regions responsible for pleiotropy between psychiatric disorders and autoimmune disorders were detected. The MHC region on chromosome 6 appears to be the most important (and it was indeed previously noted (1-3) as a confluence between schizophrenia and immune disorder risk regions), with many other regions, such as cytoband 1p13.2. We also found that most alleles shared between schizophrenia and Crohn's disease have the same effect direction, with similar trend found for other disorder pairs, such as bipolar-Crohn's disease. Our results offer a novel bird's-eye view of the genetic relationship and demonstrate strong evidence for mediated pleiotropy between psychiatric disorders and autoimmune disorders. Our findings might open new routes for prevention and treatment strategies for these disorders based on a new appreciation of the importance of immunological mechanisms in mediating risk.
Introduction
Psychiatric disorders are often associated with significant morbidity and mortality (4) . The estimated heritability for most psychiatric disorders is moderate to high (40%-80%), so genetic factors play a critical role in their etiology (5-7). In the past few years, many genome-wide association studies (GWAS) have been conducted to identify genetic risk variants that underlying psychiatric disorders (8). Despite recent progress, there still exist major challenges, and there is much yet to be discovered regarding the genetic architecture of psychiatric disorders (9).
The relationship between psychiatric disorders and autoimmune disorders has intrigued researchers for decades ( Fig. S1 ). There is a moderately large body of evidence that supports a role for autoimmune dysfunction in the development of several psychiatric disorders, including early hypothesis like the "macrophage theory of depression" (10), and recent findings such as the epidemiological observation of co-occurrence of rheumatoid arthritis (RA) and depression (11, 12) and cross-disorder drug effects, for example some drug for psychiatric disorders have anti-inflammatory properties (13, 14) . The genetic liability underlying these observed correlations has not been well studied, with the exception that recent GWAS have repeatedly identified association between SCZ and genetic variants at the major histocompatibility locus (MHC), which also plays an important role in the immune system (1) (2) (3) . However, no strong evidence of shared liability was observed between Crohn's disease (CD) and multiple psychiatric disorders in another study (15) . In genetics, the term "pleiotropy" is commonly used to describe a one-to-many relationship between a gene or mutation and phenotypes (16) . In the GWAS era, pleiotropy could explain correlations among disorders, and may also boost statistical power to detect genetic associations (15, (17) (18) (19) (20) (21) . To date, pervasive pleiotropic effects have been discovered in autoimmune disorders (22) and in psychiatric disorders (9, 15), as separate classes.
Given the public health significance of these two classes of disorders and the treatment implications of any etiological overlap, it is important to resolve the nature of any genetic pleiotropy between them, to understand the underlying mechanisms of the pleiotropy, and to identify specific genes and pathways driving such pleiotropy. These inquiries can only now be carried out because of the large amounts of genomic data that have become available in recent years. Large consortia have been formed to study many psychiatric disorders and autoimmune disorders (15, 21, (23) (24) (25) (26) (27) (28) (29) (30) . For example, the analysis results from a well-powered GWAS of schizophrenia (1) provided strong supporting evidence for the link between schizophrenia and the immune system. Undoubtedly, the availability of high-quality "omics" data offers us an unprecedented opportunity to revisit the nature of the genetic connections between psychiatric disorders and immune-mediated disorders. The analysis results can deepen our understanding of the genetic architecture of complex human diseases.
Next, we tested enrichment of immune eQTLs in the same set of 18 traits (Fig. 4) . The seven immune-mediated disorders consistently had the strongest enrichment (ranging from 2.0 to 8.5-fold). We also observed enrichment of immune eQTLs in four psychiatric disorders (SCZ, BPD, ASD, and MDD; 2.0, 2.0, 1.4, 1.6-fold, respectively), and Parkinson's disease (1.4-fold) . Those enrichment effects still persisted with CNS SNPs removed, suggesting the enrichment was not solely due to overlapped CNS SNPs also being immune eQTLs. We also observed immune eQTL enrichment in two education traits, college completion (1.39-fold) and year of education (1.46-fold) , and in three physical features, BMI (1.99-fold), obesity measured by waist-to-hip ratio adjusted BMI (2.90-fold), and height (2.97-fold).
There was even stronger enrichment of immune eQTLs among SNPs shared between five psychiatric traits (SCZ, BPD, ASD, MDD, ADHD) and CD ( Fig. S3 and SI) . Next we tested enrichment of DNase-peak located SNPs in SCZ GWAS signals from 98 ENCODE tissues (Table S7) , and found the top cell lines were from blood elements having important roles in immune response, with the top two cell lines being CD20+ B cells and Th2 cells (CD4+ T cells)( Fig. S4) .
Trend of consistent effect direction between psychiatric disorders and immune system disorders
To explore the mechanism of these pleiotropic effects further, we examined effect directions for SNPs having high posterior probabilities of being associated with both disorders. For each SNP, the same allele may increase or reduce susceptibility for the two disorders (same direction) or have opposite effects (different directions). The SCZ QQ plot (Fig. S6) shows a rise of the curve conditional on having the same effect direction with CD. We then considered four disorder pairs showing strong pleiotropy: SCZ-CD (p=1.9e-109), BPD-CD (p=1.5e-13), SCZ-Height (p=2.0e-122), and BPD-Height (p=5.4e-150). For each of these four pairs, there is no correlation in effect direction when all genotyped SNPs are considered (Table S3 ). This is expected because most SNPs are not associated with either trait. However, trends emerged after we partitioned the SNPs according to their posterior probabilities of being associated with both traits into 10 groups, and calculated the proportions of SNPs having the same effect directions for each group. There are clear patterns for SCZ-CD and BPD-CD, but not for SCZ-height nor BPD-height as shown in Fig. 5 .
In general, the higher the posterior probability of a SNP being associated with SCZ (or BPD) and CD, the more likely that the SNP had the same effect direction for the pair. For SCZ-CD, among the 85 top SNPs with posterior probabilities of association with both SCZ and CD higher than 0.9 (Table S4) , 97.6% of SNPs had the same effect directions (an allele either increases or reduces both SCZ and CD risks), with the only two oppositedirection SNPs near gene GALNT3. Similarly, for BPD-CD, in the SNP group with posterior probabilities higher than 0.8, 83% of SNPs had the same effect direction, and in the SNP group with posterior probabilities between 0.7 and 0.8, 95% of SNPs had the same effect direction for two disorders (Fig. 5) . Similar patterns were also observed for SCZ-RA and BPD-RA pairs (Fig. S7) . In contrast, for the SCZ-height pair, among the top SNPs with posterior probabilities of association with both SCZ and height higher than 0.9, 44% of the height-increasing alleles were SCZ risk alleles and the other 56% were SCZ protective alleles. In fact, the proportion of alleles that were associated with lower height and increased SCZ risk simultaneously was ~50% for all SNP groups, regardless of their posterior probabilities of being associated with both SCZ and height. Effect direction distributions across 10 posterior groups for the BPD-height pair behaved similarly.
Genome region enrichment analysis
To identify molecular pathways and networks underlying the connections between psychiatric disorders and immune-mediated disorders, we performed a series of genome region enrichment analysis. For each of the 28 disorder pairs (four psychiatric disorders and seven autoimmune disorders, with ADHD excluded due to its weak GWAS signals), we calculated the posterior probability of each SNP being associated with both traits, and plotted the posterior probabilities against genome positions ( Fig. S8) . A consistent peak in the chromosome 6 MHC region was observed for most trait pairs. There were also multiple additional recurrent or sporadic regions. To specify these regions and genes, next we performed cytoband enrichment analysis, protein-protein interaction (PPI) subnetwork detection, and gene ontology (GO) enrichment analysis.
Cytoband enrichments of SNPs with posterior probability > 0.5 were evaluated for each of the 28 disorder pairs using Fisher's exact test. Table S2 shows enriched cytobands with odds ratio (OR) > 5 and Bonferroni-adjusted p < 0.001. Under these stringent cutoffs, we found that the MHC region (6p22.1-21.3) was shared by psychiatric and autoimmune disorders (23 out of 28 pairs, SI). Apart from the MHC region, we also identified other shared regions (Table S2 ). For example, 1p13.2 was significantly enriched for the eight disorder pairs between [SCZ, BPD, MDD, and ASD] and [T1D and RA], with Bonferroni-adjusted p-values ranging from 6.8e-26 to 2.7e-78, with top SNPs located in genes AP4B1, PTPN22, and PHTF1 (Fig S9) .
With the hypothesis that there might be a common mechanism underlying the shared genetic liability between different psychiatric disorder-autoimmune disorder pairs in general, we selected SNPs with high confidence of affecting both classes of disorders (SI) and performed enrichment analysis for Gene Ontology (35) (GO) terms, KEGG pathways, and PPI networks. PPI can provide independent information for prioritization of genetic findings (36) (37) (38) (39) , and thus we constructed PPI sub-networks via DAPPLE (40) in which PPI edges are overrepresented in top SNPs (SNPs with posterior > 0.8 in at least 6 disorder pairs, Fig. S5 ). The sub-networks ( Fig. 7) highlighted include the HLA-D subfamily; a transcription activation related sub-network including multiple histones, BRD2, TUBB and ABT1; and HLA-E, HLA-F, TAP1 and TAP2. Genome annotation enrichment was performed via DAVID (41, 42) on GO (35) terms and KEGG pathways (43, 44) , with gene lists constructed with genes containing SNPs having posterior > 0.8 in at least three disorder pairs (Fig. S5) . The identified top terms of enrichment included "antigen processing and presentation," "MHC protein complex," "allograft rejection," and "NF-kappaB binding" (Table S5) , which further suggests the enrichment of immune system function in shared genetic factors between psychiatric and autoimmune disorders.
Discussion
Our results demonstrate extensive shared genetic factors between psychiatric and autoimmune disorders. First, 24 of 35 psychiatric disorder-autoimmune disorder pairs we considered yielded significant evidence for pleiotropy based on GPA analysis of summary statistics from GWAS results. Second, enrichment of immune related eQTLs in multiple psychiatric disorder GWAS signals was observed, including SCZ, BPD, ASD, and MDD. Third, much higher enrichment of immune related eQTLs in SNPs shared by psychiatric disorders and CD was observed. Fourth, enrichment of psychiatric disorder GWAS signal was observed in DNase I hypersensitivity sites in cell lines based on cellular elements with important roles in immune response. Fifth, there was a clear trend of shared SNPs having the same effect direction for SCZ-CD, SCZ-RA, BPD-CD, and BPD-RA. Finally, analyses based on posterior probabilities of SNPs being associated with both psychiatric and autoimmune disorders yielded reoccurring genomic regions, with significantly enriched cytobands and pathways. All these different lines of evidence indicate that psychiatric disorders are rather strongly genetically related to autoimmune disorders.
Beyond the evidence of pleiotropy, our results suggest how psychiatric disorders and autoimmune disorders are related genetically. Consistent with previous research, we observed a major role of MHC region for both classes of disorders, which repeatedly stood out among multiple analyses. Specific proteins in MHC regions were prioritized via constructing overrepresented protein-protein interaction sub-networks. Specifically, those protein-protein interaction clusters most responsible for shared genetic components between psychiatric disorders and autoimmune disorders in these data were: (1) three minor gene subunits HLA-E, HLA-F, and HLA-G, but not the three major gene subunits, interacting with TAP1, TAP2. TAP1 and TAP2 are transporters associated with antigen processing, which cooperate with MHC class I to present antigens (45); (2) Interaction between HLA DO, DM, and DR proteins; and (3) a set of genes with important roles in transcriptional activation, including BRD2, TUBB, ABT1, and multiple histone coding genes.
The MHC is not the only genomic region contributing to the connection between psychiatric disorders and autoimmune disorders. First, we observed enrichment of immune eQTLs even after the whole MHC region was removed ( Fig. S10) . Second, cytoband enrichment results indicate roles played by other specific genomic regions, such as 1p13.2, harboring gene PTPN22 ("Protein Tyrosine Phosphatase, Non-Receptor Type 22 (Lymphoid)"), which was also prioritized in our PPI analysis.
Our work pinpoints these specific genetic regions, genes, proteins, and pathways, which potentially connect psychiatric disorders and immune disorders genetically and therefore etiologically. These specific genes might be considered as starting points for follow-up experiments concerning the etiological linkage of those two classes of disorders. Furthermore, our findings might be used in developing novel drugs that treat psychiatric disorders by modulating immune system function, which would nicely complement the limited existing treatment options for these psychiatric disorders.
The observation of a tendency of the same effect direction for SNPs associated with either SCZ and BPD paired with CD gives some insight concerning the underlying mechanism of their shared genetic factors. Pleiotropy has been extensively reviewed (16, (46) (47) (48) , but is still not well understood in terms of its extent, mechanisms, and consequences. The Weak Hypothesis of Universal Pleiotropy (WHUP) advocated by Fisher (49) and Wright (50) is based on two assumptions that, in general, a phenotype might be influenced by many variants, and a variant might cause changes to many phenotypes. This basic idea finds considerable support in GWAS findings, and fits the Common-Disease Common-Variant (CDCV) hypothesis. Under WHUP, extensive pleiotropy should be detected between phenotypes. In this case though, the effect directions of shared genetic variants should be about random. Therefore, our results suggest that it is unlikely that the shared genetic factors between psychiatric and autoimmune disorders originate from universal pleiotropy (or a tendency of GWAS to identify SNPs that are functional and for SNPs that are functional to be those that are most likely to influence various traits); rather, our observation supports a closer genetic relationship between those two types of disorders. Various molecular mechanisms could result in pleiotropy (48) . There are biological pleiotropy, mediated pleiotropy, and spurious pleiotropy. Biological pleiotropy has separate causal paths for different phenotypes, while mediated pleiotropy has one phenotype lying on another phenotype's causal path; thus by this mechanism, one phenotype might lead to another (48) . Our results, the striking trend of shared SNPs for SCZ and CD acting in the same direction, can be best explained by mediated pleiotropy. This, together with our observation of pervasive enrichment of immune eQTLs in psychiatric disorders, and the lack of enrichment of CNS SNPs (immune eQTLs excluded) in immune-mediated disorders (except MS, which is characterized by CNS pathology), suggest that autoimmune disorders might mediate psychiatric disorder risk, i.e. some downstream autoimmune dysfunctions might be a trigger to some psychiatric disorders (or subtypes).
We observed considerable enrichment of immune-related eQTLs in traits of body features (height, BMI, and WHR-adjusted BMI), which are consistent with previous experiments that BMI is correlated with immune parameters (51) , and that height is associated with immune response in young men (52) . Therefore, our results further confirm the relationship between body somatic features (BMI and height) and immune system from a genomics perspective. The enrichment of CNS SNPs in two educational traits is consistent with the notion that educational attainment is related to CNS development.
Although our analyses were based on results from GWAS consortia, the statistical power remains limited to identify the majority of disease associated variants for these disorders. GWAS results from larger studies and improved statistical and bioinformatics approaches will enable us to identify more shared genetic pathways between these classes of disorders, and as always -despite the very high significance levels we observed for some relationships -independent replication of our results is called for.
Materials and Methods

Genome-wide Association Study (GWAS) Data Sources
We made use of GWAS summary statistics from a set of diverse and representative traits, including major psychiatric disorders, various immune system disorders, multiple metabolic diseases and metabolism related traits, body morphological features, and some socioeconomic measures ( Table 1 ). The p-values were available for all traits, but only some of them have available specified alleles and their corresponding beta or odds ratios indicating effect direction.
Genomic Annotation Data Sources
Central nervous system (CNS) genes were identified in a previous study (53) , comprising preferentially brain-expressed genes (53), neuronal-activity genes (54), learning-related genes (55) , and synapse genes, defined by Gene Ontology (35) . A complete list of these genes is given in Table S6 . CNS SNPs were defined as SNPs located within CNS genes with 50kb extension at each end. To investigate immune system influence, we used context-specific eQTLs upon triggering immune response as detected by Fairfax et al. (56) , where interferon-γ and lipopolysaccharide (LPS) were used as inflammatory proxies to stimulate innate immune effects in monocytes from volunteers of European ancestry. We used a union of eQTLs detected in different contexts as a set of immunerelated eQTLs in our study. In total, we have 94,674 immune eQTLs and 199,202 CNS SNPs, of which 24,860 CNS SNPs are also immune eQTLs. To investigate the impact of chromatin state, we used DNase I hypersensitivity sites extracted from ENCODE (57) DNase-seq peaks and signal of open chromatin from 125 cell lines.
Statistical Methods
Pleiotropy analysis was performed via the GPA R package (31) , which uses a statistical approach to exploring the genetic architecture of complex traits by integrating pleiotropy and functional annotation information, including prioritizing risk genetic variants, evaluating annotation enrichment and pleiotropy by hypothesis testing. GPA does not need individual level genotype-phenotype data, making it particularly useful for largescale integrative analysis. We briefly describe the parameters and their interpretations in the GPA model in Supporting Information, and more details can be found in (31) .
Genome annotation enrichment was carried out using DAVID (41, 42) ; PPI sub-networks were generated using DAPPLE (40) . Cytoband position information was downloaded from the UCSC Table Browser (58) . Cytoband enrichment was tested using Fisher's exact test, with p-values adjusted using Bonferroni correction Dunn (59) . Cytoband enrichment test based on posterior probability 5
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GPA method description
GPA (1) is a statistical approach to exploring the genetic architecture of complex traits by integrating pleiotropy and functional annotation information, including prioritizing risk genetic variants, evaluating annotation enrichment and pleiotropy by hypothesis testing. Instead of relying on genotype-phenotype data at the individual level, it only requires the summary statistics from GWAS, which makes it useful for integrative analysis of genomic data. For completeness, we briefly introduce the GPA model here.
Consider the p-values { ! , … , ! } obtained by performing hypothesis testing of genomewide SNPs from one GWAS, where is the number of SNPs. In the GPA model, these p-values are assumed to come from a mixture of null (un-associated) and non-null (associated), with probability ! and ! = 1 − ! , respectively. GPA uses the Uniform distribution on [0,1] and the Beta distribution with parameters ( , 1) to model the pvalues from the null and non-null groups, respectively. Let ! ∈ {0,1} be the latent variable indicating whether the -th SNP is from the null or non-null group, where ! = 0 means null and ! = 1 means non-null. Then the GPA model for one GWAS without annotation can be written as:
GPA further incorporates functional annotation as follows. Let an -dimensional vector collect functional information from an annotation source, where ! ∈ {0, 1} indicates whether the j-th SNP is a functional unit according to the annotation source. For example, given an eQTL data, if the j-th SNP is an eQTL, then ! = 1, otherwise ! = 0. The relationship between ! and ! is described as:
Clearly, ! can be interpreted as the proportion of null SNPs being annotated, ! corresponds to the proportion of non-null SNPs being annotated, and ! > ! implies that there exists enrichment in this annotation. In our study, the ratio ! / ! is define as enrichment fold measuring the strength of enrichment in various annotations.
An efficient Expectation-Maximization (EM) algorithm has been developed to adaptively estimate the model parameters ! , ! , 0 , 1 , . After that, SNPs can be prioritized based on their local false discovery rates (FDR). When there is no annotation data, the local FDR is defined as the probability that the j-th SNP belongs to the null group given its pvalue, i.e., ( ! ) = ( ! = 0| ! ). With annotation data, the FDR can be calculated
(2) ( ! , ! ) = ( ! = 0| ! , ! ). We can use the likelihood ratio test to assess the significance of its enrichment. Specifically, the significance of enrichment of an annotation for GWAS can be assessed by testing ! ∶ ! = ! versus ! ∶ ! ≠ ! . Standard errors of all the parameters can also be calculated.
The extension of the above model to handle two GWAS is straightforward. Suppose the p-values from two GWAS have been collected in an × 2 matrix = [ ], where !" denotes the p-value of the -th SNP in the -th GWAS, = 1, 2. Let ! ∈ {00, 10, 01, 11} indicate the association between the -th SNP and the two phenotypes: ! = 00 means the -th SNP is associated with neither of them, ! = 10 means it is only associated with the first one, ! = 01 means it is only associated with the second one, and = 11 means it is associated with both. Then the two-groups model (1) can be extended to the following four-groups model:
Similarly, functional annotation information can be incorporated into the multiple GWAS model (3) in the following way:
where !! is the probability of a null SNP being annotated, !" is the probability of the first phenotype associated-SNP being annotated, !" is the probability of the second phenotype associated-SNP being annotated, and !! is the probability of jointly associated-SNP being annotated. For joint analysis of two GWAS data sets, the local FDR calculation and enrichment assessment can be done in a similar way. In addition, the pleiotropy between two phenotypes can be tested in a statistically rigorous way. When there is no pleiotropy, i.e., the signals from the two GWAS are independent of each other, testing pleiotropy can be formulated by testing the following hypothesis:
where ! * = !" + !! and * ! = !" + !! . The likelihood ratio test statistic
asymptotically follows χ 2 distribution with df = 1 under the null.
More details about the GPA approach have been discussed in (1) .
Enrichment of immune-eQTLs in SNPs shared by psychiatric disorders and autoimmune disorders
To explore this hypothesis further, we tested levels of enrichment of immune related eQTLs in SNPs associated with both psychiatric disorders and Crohn's disease, and observed large enrichment ratios. Our result shows that, among the immune related eQTLs, the ratios ( !! / !! ) of the group of SNPs associated with both diseases and the group of SNPs associated with neither diseases are SCZ-CD 3.9 (s.e.=0.06), BPD-CD 4.4(s.e.=0.09), ASD-CD 3.4(s.e.=0.2), MDD-CD 4.6(s.e.=0.18), and ADHD-CD 2.1(s.e.=0.45) (Fig. S3) . The ratios with respect to SNPs associated with only one disease ( !" / !! and !" / !! ) are much lower, suggesting that the shared genetic components between the 5 psychiatric disorders and CD are closely related to immune function.
Enrichment of DNase-Peak SNPs in schizophrenia GWAS
DNase-Peak dataset was downloaded from ENCODE for 125 cell lines, and there were 98 cell lines after removing 27 cancer cell lines (Table S7) . Although limited in cell lines from brain regions, those 98 cell lines have great coverage for various blood cells, making it suitable for studying whether there is enrichment of functional genomic regions in SCZ GWAS tissues implicated with important immune functions. DNase-Peak SNPs are SNPs located in or within 1kb from DNase-Peaks. A cluster of blood originated cell lines is the top cell lines in our analysis (Fig. S4) .
Cytoband enrichment test based on posterior probability
Cytoband position was downloaded from the UCSC Table Browser (2), with 862 entries of cytobands in total. Enrichment tests were carried out on 28 pairs of disease pairs, between seven autoimmune disorders (CD, UC, MS, PS, RA, SLE, and T1D) and four psychiatric disorders (SCZ, BPD, MDD, and ASD). For each disease pair, potential shared SNPs were selected based on posterior of being associated with both diseases Pr( ! = 1)>0.5. Numbers of potential shared SNPs vary from disease to disease, ranging from 0 to 4,505 (for SCZ-CD). For each cytoband, we calculated { !! , !" , !" , !! }, with !! being the number SNPs in cytoband that are potential shared SNPs, !" being the number of SNPs in cytoband that are not potential shared SNPs, !" being the number of potential shared SNPs not in cytoband, and !! being the number of SNPs not in cytoband and are not potential shared SNPs. We then tested the deviation from null hypothesis that { !! , !" , !" , !! } follows hypergeometic distribution using Fisher's exact test and adjust p-values for multiple testing using Bonferroni correction Dunn (3).
A complete list of all cytobands with enrichment odds ratio (OR) >5 and Bonferroniadjusted p-value<0.001 in at least one disease pair were reported (Table S2 ). Some cytobands have significant enrichment in more than one disease pairs, such as MHC region and 1p13.2, indicating their role in affecting both psychiatric disorders and autoimmune disorders. Recombination rate (cM/Mb) Recombination rate (cM/Mb) 
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Table S1 (Separate Excel File) Strength of pleiotropy within and across two disorder classes: 5 psychiatric disorders and 7 autoimmune disorders. 
